These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

898 related articles for article (PubMed ID: 27845732)

  • 41. Targeting PI3K/AKT/mTOR network for treatment of leukemia.
    Bertacchini J; Heidari N; Mediani L; Capitani S; Shahjahani M; Ahmadzadeh A; Saki N
    Cell Mol Life Sci; 2015 Jun; 72(12):2337-47. PubMed ID: 25712020
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.
    Slomovitz BM; Coleman RL
    Clin Cancer Res; 2012 Nov; 18(21):5856-64. PubMed ID: 23082003
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Suppression of MYC by PI3K/AKT/mTOR pathway inhibition in combination with all-trans retinoic acid treatment for therapeutic gain in acute myeloid leukaemia.
    Stengel S; Petrie KR; Sbirkov Y; Stanko C; Ghazvini Zadegan F; Gil V; Skopek R; Kamiński P; Szymański Ł; Brioli A; Zelent A; Schenk T
    Br J Haematol; 2022 Jul; 198(2):338-348. PubMed ID: 35468223
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.
    Tamburini J; Chapuis N; Bardet V; Park S; Sujobert P; Willems L; Ifrah N; Dreyfus F; Mayeux P; Lacombe C; Bouscary D
    Blood; 2008 Jan; 111(1):379-82. PubMed ID: 17878402
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bone mesenchymal stem cell-derived exosomal microRNA-7-5p inhibits progression of acute myeloid leukemia by targeting OSBPL11.
    Jiang D; Wu X; Sun X; Tan W; Dai X; Xie Y; Du A; Zhao Q
    J Nanobiotechnology; 2022 Jan; 20(1):29. PubMed ID: 35012554
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells.
    Han L; Qiu P; Zeng Z; Jorgensen JL; Mak DH; Burks JK; Schober W; McQueen TJ; Cortes J; Tanner SD; Roboz GJ; Kantarjian HM; Kornblau SM; Guzman ML; Andreeff M; Konopleva M
    Cytometry A; 2015 Apr; 87(4):346-56. PubMed ID: 25598437
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
    Zhou Q; Lui VW; Yeo W
    Future Oncol; 2011 Oct; 7(10):1149-67. PubMed ID: 21992728
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeted Inhibition of the PI3K/Akt/mTOR Signaling Axis: Potential for Sarcoma Therapy.
    Wani AK; Singh R; Akhtar N; Prakash A; Nepovimova E; Oleksak P; Chrienova Z; Alomar S; Chopra C; Kuca K
    Mini Rev Med Chem; 2024; 24(16):1496-1520. PubMed ID: 38265369
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Human umbilical cord mesenchymal stem cells derived exosomes exert antiapoptosis effect via activating PI3K/Akt/mTOR pathway on H9C2 cells.
    Liu H; Sun X; Gong X; Wang G
    J Cell Biochem; 2019 Sep; 120(9):14455-14464. PubMed ID: 30989714
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
    Polivka J; Janku F
    Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PI3K/Akt/mTOR pathway dual inhibitor BEZ235 suppresses the stemness of colon cancer stem cells.
    Chen J; Shao R; Li F; Monteiro M; Liu JP; Xu ZP; Gu W
    Clin Exp Pharmacol Physiol; 2015 Dec; 42(12):1317-26. PubMed ID: 26399781
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia.
    Park S; Chapuis N; Tamburini J; Bardet V; Cornillet-Lefebvre P; Willems L; Green A; Mayeux P; Lacombe C; Bouscary D
    Haematologica; 2010 May; 95(5):819-28. PubMed ID: 19951971
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel drug therapies in myeloid leukemia.
    Horne GA; Kinstrie R; Copland M
    Pharm Pat Anal; 2015; 4(3):187-205. PubMed ID: 26030080
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era.
    Liu ST; Hui G; Mathis C; Chamie K; Pantuck AJ; Drakaki A
    Clin Genitourin Cancer; 2018 Apr; 16(2):e269-e276. PubMed ID: 29199023
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rapamycin interacts synergistically with idarubicin to induce T-leukemia cell apoptosis in vitro and in a mesenchymal stem cell simulated drug-resistant microenvironment via Akt/mammalian target of rapamycin and extracellular signal-related kinase signaling pathways.
    Wu KN; Zhao YM; He Y; Wang BS; Du KL; Fu S; Hu KM; Zhang LF; Liu LZ; Hu YX; Wang YJ; Huang H
    Leuk Lymphoma; 2014 Mar; 55(3):668-76. PubMed ID: 23741975
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Salidroside via ERK1/2 and PI3K/AKT/mTOR signal pathway induces mouse bone marrow mesenchymal stem cells differentiation into neural cells].
    Chen YN; Liu H; Zhao HB; Liu Y; Bai J; Zhu XJ; Wang Y
    Yao Xue Xue Bao; 2013 Aug; 48(8):1247-52. PubMed ID: 24187831
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular alterations of PI3K/Akt/mTOR pathway: a therapeutic target in endometrial cancer.
    Pavlidou A; Vlahos NF
    ScientificWorldJournal; 2014; 2014():709736. PubMed ID: 24526917
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
    Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
    Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeting mTOR signaling pathways and related negative feedback loops for the treatment of acute myeloid leukemia.
    Carneiro BA; Kaplan JB; Altman JK; Giles FJ; Platanias LC
    Cancer Biol Ther; 2015; 16(5):648-56. PubMed ID: 25801978
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dual Inhibition of PI3K/Akt and mTOR by the Dietary Antioxidant, Delphinidin, Ameliorates Psoriatic Features In Vitro and in an Imiquimod-Induced Psoriasis-Like Disease in Mice.
    Chamcheu JC; Adhami VM; Esnault S; Sechi M; Siddiqui IA; Satyshur KA; Syed DN; Dodwad SM; Chaves-Rodriquez MI; Longley BJ; Wood GS; Mukhtar H
    Antioxid Redox Signal; 2017 Jan; 26(2):49-69. PubMed ID: 27393705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.